Share this article on:

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

Palella, Frank J. Jra; Fisher, Martinb; Tebas, Pabloc; Gazzard, Briand; Ruane, Petere; Van Lunzen, Janf; Shamblaw, Davidg; Flamm, Jasonh; Ebrahimi, Ramini; Porter, Daniellei; White, Kirsteni; Hindman, Jasoni; Elbert, Elizabethi; De-Oertel, Shampai; Fralich, Toddi


The authors bring the following errors in their paper [1] to the attention of readers.

In the third sentence of the first paragraph of the Results on page 337, the percentage of participants who switched to RPV/FTC/TDF should be 96% instead of 94%, and who completed 24 weeks of RPV/FTC/TDF treatment should be 90% instead of 89%.

In Figure 1 on page 338, of the 159 that were randomized to stay on PI+RTV+2NRTIs and received at least one dose, for those that discontinued study before switching to RPV/FTC/TDF for ‘Withdrew consent’ it should be 3 instead of 4, and 1 for an additional reason of ‘Protocol violation’. Of the 152 that switched to RPV/FTC/TDF at week 24, for those that discontinued after switching due to ‘Withdrew consent’ should be 2 instead of 1 and for ‘Protocol violation’ should be 1 instead of 2. The corrected Figure 1 is below.

On page 339, Table 1 the entry for CD4+ cell count (cells/μL) should say ‘Mean (SD)’ and not ‘Median (SD)’.

On page 341, Figure 2 the value for HDL for RPV/FTC/TDF (immediate, D1-W24) should be -4 mg/dl instead of -6 mg/dl and for RPV/FTC/TDF (delayed, W24-W48) should be -2 mg/dl instead of -4 mg/dl. The corrected upper panel of the figure is below.

AIDS. 28(13):1999-2000, August 24th, 2014.

doi: 10.1097/QAD.0000000000000087
Clinical Science

Objective: To evaluate the efficacy and safety of antiretroviral simplification from a ritonavir-boosted protease inhibitor-based regimen [protease inhibitor+RTV+two nucleos(t)ide reverse transcriptase inhibitors (NRTIs); ≥6 months of exposure prior to study entry with no prior treatment failure] to the single-tablet regimen (STR) rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) in virologically suppressed, HIV-1-infected participants.

Design: Phase 3b, randomized, open-label, international, 48-week switch study.

Methods: Participants were randomized 2 : 1 to switch to RPV/FTC/TDF immediately or stay on their baseline protease inhibitor+RTV+2NRTIs regimen with a delayed switch to RPV/FTC/TDF at week 24. The primary endpoint was noninferiority (12% margin) of RPV/FTC/TDF compared with protease inhibitor+RTV+ two NRTIs in maintaining plasma HIV-1 RNA less than 50 copies/ml at week 24 by Snapshot analysis.

Results: A total of 476 participants were randomized and received at least one dose of study drug. Demographics and baseline characteristics were similar between arms. The primary objective of noninferiority at week 24 was met: HIV-1 RNA less than 50 copies/ml by Snapshot analysis, 93.7% of RPV/FTC/TDF versus 89.9% of protease inhibitor+RTV+ two NRTIs (difference 3.8%, 95% confidence interval −1.6 to 9.1%). Through week 48, 89.3% of participants in the immediate switch group maintained virologic suppression. High rates of suppression were maintained with RPV/FTC/TDF regardless of participant's pre-antiretroviral HIV-1 RNA level. Overall development of resistance mutations after switching to RPV/FTC/TDF was low. Decreases in total cholesterol, low-density lipoprotein (LDL), and triglycerides were significantly greater among RPV/FTC/TDF recipients than those in the protease inhibitor+RTV+ two NRTIs group.

Conclusion: Switching to the STR RPV/FTC/TDF from an RTV-boosted protease inhibitor regimen in virologically suppressed, HIV-1-infected participants maintained virologic suppression with a low risk of virologic failure, while improving total cholesterol, LDL, and triglycerides.

Supplemental Digital Content is available in the text

aNorthwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

bBrighton and Sussex University Hospitals, Brighton, UK

cUniversity of Pennsylvania, Division of Infectious Diseases, Clinical Trials Unit, Philadelphia, Pennsylvania, USA

dChelsea and Westminster Hospital Foundation Trust, London, UK

ePeter Ruane, MD, Inc., Los Angeles, California, USA

fUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany

gLa Playa Medical Group and Clinical Research, San Diego

hKaiser Permanente, Sacramento

iGilead Sciences Inc., Foster City, California, USA.

Correspondence to Todd Fralich, MD, 333 Lakeside Drive, Foster City, CA 94404, USA. E-mail:

Received 28 March, 2013

Revised 28 August, 2013

Accepted 17 September, 2013

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

© 2014 Lippincott Williams & Wilkins, Inc.